Severe eosinophilic asthma (SEA) has been associated with T-helper type 2 (Th2) inflammatory response. A good understanding of T cell functions in asthma is important for therapy, especially in the choice of biological treatments for severe cases. Mepolizumab, an IL-5 antagonist, is indicated for the treatment of severe asthma. Regulatory T cells (Tregs) suppress inflammation by secreting cytokines that inhibit Th2 cell proliferation.
Bergantini, L., D'Alessandro, M., Cameli, P., Bono, C., Perruzza, M., Biagini, M., et al. (2021). Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, e13031 [10.1111/sji.13031].
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab
Bergantini, Laura;d'Alessandro, Miriana;Cameli, Paolo;Bono, Clara;Sestini, Piersante;Dotta, Francesco;Bargagli, Elena
2021-01-01
Abstract
Severe eosinophilic asthma (SEA) has been associated with T-helper type 2 (Th2) inflammatory response. A good understanding of T cell functions in asthma is important for therapy, especially in the choice of biological treatments for severe cases. Mepolizumab, an IL-5 antagonist, is indicated for the treatment of severe asthma. Regulatory T cells (Tregs) suppress inflammation by secreting cytokines that inhibit Th2 cell proliferation.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1129092
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo